Concise review: The heterogenous roles of BATF3 in cancer oncogenesis and dendritic cells and T cells differentiation and function considering the importance of BATF3-dependent dendritic cells

• Published in: Immunogenetics (New York) 2024-04, Vol.76 (2), p.75-91
• Main Authors: Dabbaghipour, Reza, Ahmadi, Elham, Entezam, Mona, Farzam, Omid Rahbar, Sohrabi, Sepideh, Jamali, Sajjad, Sichani, Ali Saber, Paydar, Hadi, Baradaran, Behzad
• Format: Article
• Language: English
• Subjects: Allergology; Biological activity; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer immunotherapy; CD103 antigen; CD8 antigen; Cell Biology; Cell differentiation; Cell-mediated immunity; Dendritic cells; Dendritic structure; Differentiation (biology); Foxp3 protein; Gene Function; Human Genetics; Immunological tolerance; Immunology; Immunosurveillance; Immunotherapy; Interferon regulatory factor 4; Intracellular; Leucine; Leucine zipper proteins; Lymphocytes; Lymphocytes T; Malignancy; Parasites; Pathogens; Review; Transcription factors; Tumor microenvironment; Tumorigenesis; Vaccination
• ISSN: 0093-7711; 1432-1211
• DOI: 10.1007/s00251-024-01335-x

The transcription factor, known as basic leucine zipper ATF-like 3 (BATF3), is a crucial contributor to the development of conventional type 1 dendritic cells (cDC1), which is definitely required for priming CD8 + T cell-mediated immunity against intracellular pathogens and malignancies. In this respect, BATF3-dependent cDC1 can bring about immunological tolerance, an autoimmune response, graft immunity, and defense against infectious agents such as viruses, microbes, parasites, and fungi. Moreover, the important function of cDC1 in stimulating CD8 + T cells creates an excellent opportunity to develop a highly effective target for vaccination against intracellular pathogens and diseases. BATF3 has been clarified to control the development of CD8α + and CD103 + DCs. The presence of BATF3-dependent cDC1 in the tumor microenvironment (TME) reinforces immunosurveillance and improves immunotherapy approaches, which can be beneficial for cancer immunotherapy. Additionally, BATF3 acts as a transcriptional inhibitor of Treg development by decreasing the expression of the transcription factor FOXP3. However, when overexpressed in CD8 + T cells, it can enhance their survival and facilitate their transition to a memory state. BATF3 induces Th9 cell differentiation by binding to the IL-9 promoter through a BATF3/IRF4 complex. One of the latest research findings is the oncogenic function of BATF3, which has been approved and illustrated in several biological processes of proliferation and invasion.